Jialin Wei
Overview
Explore the profile of Jialin Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Zhao X, Hao M, Zhang X, Wei J, Feng S, He Y, et al.
Onco Targets Ther
. 2023 Dec;
16:1055-1059.
PMID: 38144903
The neurotrophic receptor tyrosine kinase (NTRK) gene fusions occur in a large number of solid tumors and tropomyosin receptor kinase (TRK) inhibitors exhibit attractive antitumor activity. However, the occurrence of...
22.
Chen X, Zheng X, Lu N, Zhang R, Zhai W, Ma Q, et al.
Int Immunopharmacol
. 2023 Nov;
125(Pt A):111165.
PMID: 37935091
Objective: Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a serious life-threatening complication. The granulocyte colony-stimulated factor mobilized donor lymphocyte infusions (gDLI) combined with chemotherapy is currently a commonly...
23.
Shen Y, Yang D, Zhang R, Chen X, Ma Q, Wei J, et al.
Front Oncol
. 2023 Oct;
13:1256043.
PMID: 37901324
SET-NUP214 fusion gene, also known as TAF-1-CAN and SET-CAN, is observed in acute myeloid leukemia (AML) and T-cell lymphoblastic leukemia (T-ALL). SET-NUP214 fusion in T-cell lymphoblastic leukemia is associated with...
24.
Zheng X, Gao H, Lu N, Wang M, Zhang H, Zheng Y, et al.
Ann Hematol
. 2023 Oct;
102(12):3603-3611.
PMID: 37878011
This prospective clinical investigation focused on the addition of venetoclax and decitabine to myeloablative conditioning regimens, targeting high-risk and elderly individuals undergoing allogeneic hematopoietic stem cell transplantation. In total, 19...
25.
Cao Y, Zheng X, Zhang H, Wang M, Guo W, Chen X, et al.
Hematol Oncol
. 2023 Oct;
42(1):e3232.
PMID: 37793012
Recurrence following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major cause of treatment failure in patients with myeloid malignancy. Azacytidine (AZA) maintenance is a promising therapy to prevent relapse...
26.
Wang M, Zhang H, Zheng X, Liu J, Wang J, Cao Y, et al.
Hematol Oncol
. 2023 Sep;
42(1):e3230.
PMID: 37752767
Autologous hematopoietic stem cell transplantation (auto-HSCT), matched sibling donor HSCT (MSD-HSCT), and alternative donor HSCT (AD-HSCT) are viable post-remission treatment options for acute myeloid leukemia (AML). A total of 283...
27.
Guo W, Cao Y, Liu J, Zheng X, Wang M, Zheng Y, et al.
Bone Marrow Transplant
. 2023 Jul;
58(10):1163-1166.
PMID: 37474728
No abstract available.
28.
Shen Y, Zhang T, Zhang L, Zhen S, Chen Z, Zhang R, et al.
Bone Marrow Transplant
. 2023 Jul;
58(10):1149-1151.
PMID: 37420010
No abstract available.
29.
Liu L, Pei X, Ma R, He Y, Zhang R, Wei J, et al.
Blood Sci
. 2023 May;
5(2):106-110.
PMID: 37228774
Invasive fungal diseases (IFDs) are major and lethal infectious complications for patients with neutropenia after chemotherapy. Prophylaxis with intravenous and oral suspended itraconazole (200 mg Q12h intravenously × 2 days...
30.
Chen X, Ma Y, Zhang R, Zhai W, Ma Q, Pang A, et al.
Hematology
. 2023 May;
28(1):2212943.
PMID: 37219061
Objective: To investigate the preventive effect of low-dose porcine anti-thymocyte globulin (P-ATG) on graft versus host disease (GVHD) in patients' donors over 40 years old or female donors undergoing HLA-matched...